These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 23775002)

  • 21. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.
    Hessell AJ; Rakasz EG; Poignard P; Hangartner L; Landucci G; Forthal DN; Koff WC; Watkins DI; Burton DR
    PLoS Pathog; 2009 May; 5(5):e1000433. PubMed ID: 19436712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.
    Bogers WM; Davis D; Baak I; Kan E; Hofman S; Sun Y; Mortier D; Lian Y; Oostermeijer H; Fagrouch Z; Dubbes R; van der Maas M; Mooij P; Koopman G; Verschoor E; Langedijk JP; Zhao J; Brocca-Cofano E; Robert-Guroff M; Srivastava I; Barnett S; Heeney JL
    Virology; 2008 Dec; 382(2):217-25. PubMed ID: 18947849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.
    Mascola JR; Stiegler G; VanCott TC; Katinger H; Carpenter CB; Hanson CE; Beary H; Hayes D; Frankel SS; Birx DL; Lewis MG
    Nat Med; 2000 Feb; 6(2):207-10. PubMed ID: 10655111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies.
    Ruprecht RM; Hofmann-Lehmann R; Smith-Franklin BA; Rasmussen RA; Liska V; Vlasak J; Xu W; Baba TW; Chenine AL; Cavacini LA; Posner MR; Katinger H; Stiegler G; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Montefiori DC; McClure HM
    Transfus Clin Biol; 2001 Aug; 8(4):350-8. PubMed ID: 11642027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
    Xiao P; Zhao J; Patterson LJ; Brocca-Cofano E; Venzon D; Kozlowski PA; Hidajat R; Demberg T; Robert-Guroff M
    J Virol; 2010 Jul; 84(14):7161-73. PubMed ID: 20444898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA vaccine protection against challenge with simian/human immunodeficiency virus 89.6 in rhesus macaques.
    Habel A; Chanel C; Le Grand R; Martinon F; Couillin L; Moog C; Doms R; Gauduin MC; Hurtrel B; Guillet JG; Aubertin AM; Girard M
    Dev Biol (Basel); 2000; 104():101-5. PubMed ID: 11713807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies.
    Ferrantelli F; Rasmussen RA; Buckley KA; Li PL; Wang T; Montefiori DC; Katinger H; Stiegler G; Anderson DC; McClure HM; Ruprecht RM
    J Infect Dis; 2004 Jun; 189(12):2167-73. PubMed ID: 15181562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.
    Burton DR; Hessell AJ; Keele BF; Klasse PJ; Ketas TA; Moldt B; Dunlop DC; Poignard P; Doyle LA; Cavacini L; Veazey RS; Moore JP
    Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11181-6. PubMed ID: 21690411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying
    Scinto HB; Gupta S; Thorat S; Mukhtar MM; Griffiths A; Delgado J; Plake E; Vyas HK; Strickland A; Byrareddy SN; Montefiori DC; LaBranche C; Pal R; Treece J; Orndorff S; Ferrari MG; Weiss D; Chenine AL; McLinden R; Michael N; Kim JH; Robb ML; Rerks-Ngarm S; Pitisuttithum P; Nitayaphan S; Ruprecht RM
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29743361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.
    Pal R; Kalyanaraman VS; Nair BC; Whitney S; Keen T; Hocker L; Hudacik L; Rose N; Mboudjeka I; Shen S; Wu-Chou TH; Montefiori D; Mascola J; Markham P; Lu S
    Virology; 2006 May; 348(2):341-53. PubMed ID: 16460776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.
    Mascola JR; Lewis MG; Stiegler G; Harris D; VanCott TC; Hayes D; Louder MK; Brown CR; Sapan CV; Frankel SS; Lu Y; Robb ML; Katinger H; Birx DL
    J Virol; 1999 May; 73(5):4009-18. PubMed ID: 10196297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response.
    Sui Y; Lewis GK; Wang Y; Berckmueller K; Frey B; Dzutsev A; Vargas-Inchaustegui D; Mohanram V; Musich T; Shen X; DeVico A; Fouts T; Venzon D; Kirk J; Waters RC; Talton J; Klinman D; Clements J; Tomaras GD; Franchini G; Robert-Guroff M; Trinchieri G; Gallo RC; Berzofsky JA
    J Clin Invest; 2019 Mar; 129(3):1314-1328. PubMed ID: 30776026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env.
    Song RJ; Chenine AL; Rasmussen RA; Ruprecht CR; Mirshahidi S; Grisson RD; Xu W; Whitney JB; Goins LM; Ong H; Li PL; Shai-Kobiler E; Wang T; McCann CM; Zhang H; Wood C; Kankasa C; Secor WE; McClure HM; Strobert E; Else JG; Ruprecht RM
    J Virol; 2006 Sep; 80(17):8729-38. PubMed ID: 16912320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge.
    Davis D; Koornstra W; Fagrouch Z; Verschoor EJ; Heeney JL; Bogers WM
    PLoS One; 2013; 8(8):e72702. PubMed ID: 23977339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis.
    Siddappa NB; Hemashettar G; Wong YL; Lakhashe S; Rasmussen RA; Watkins JD; Novembre FJ; Villinger F; Else JG; Montefiori DC; Ruprecht RM
    J Med Primatol; 2011 Apr; 40(2):120-8. PubMed ID: 21044092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective effects of nef-deleted SHIV or that having IFN-gamma against disease induced with a pathogenic virus early after vaccination.
    Enose Y; Kita M; Yamamoto T; Suzuki H; Miyake A; Horiuchi R; Ibuki K; Kaneyasu K; Kuwata T; Takahashi E; Sakai K; Shinohara K; Miura T; Hayami M
    Arch Virol; 2004 Sep; 149(9):1705-20. PubMed ID: 15593414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.
    Sundling C; O'Dell S; Douagi I; Forsell MN; Mörner A; Loré K; Mascola JR; Wyatt RT; Karlsson Hedestam GB
    J Virol; 2010 Sep; 84(18):9086-95. PubMed ID: 20610729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
    Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
    Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences.
    Tartaglia LJ; Chang HW; Lee BC; Abbink P; Ng'ang'a D; Boyd M; Lavine CL; Lim SY; Sanisetty S; Whitney JB; Seaman MS; Rolland M; Tovanabutra S; Ananworanich J; Robb ML; Kim JH; Michael NL; Barouch DH
    PLoS Pathog; 2016 Feb; 12(2):e1005431. PubMed ID: 26849216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.